An evaluation of the safety, tolerability, and pharmacodynamic effects of GSK189075 [remogliflozin etabonate] when administered with furosemide or hydrochlorothiazide.

Trial Profile

An evaluation of the safety, tolerability, and pharmacodynamic effects of GSK189075 [remogliflozin etabonate] when administered with furosemide or hydrochlorothiazide.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Mar 2012

At a glance

  • Drugs Furosemide; Hydrochlorothiazide; Remogliflozin etabonate
  • Indications Heart failure; Hypertension; Obesity; Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 27 Oct 2008 Actual end date (May 2008) added as reported by ClinicalTrials.gov.
    • 27 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top